NEW YORK (GenomeWeb) – BioAge Labs, an early-stage drug discovery firm, recently raised $10.9 million to develop therapies that could extend a person's lifespan.
The Berkeley, California-based company has also partnered with the Estonian Genome Center to access various data related to long-lived individuals in the northern European country, which has enabled BioAge to craft bioinformatic tools that it claims can identify the molecular signatures of aging.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
